A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

A Phase 1, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.

Study Overview

• Status: Completed
• Conditions: Peanut Allergy
• Intervention / Treatment: Drug: ASP0892; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • Arkansas Children's Hospital Research Institute
  • California
    • Mountain View, California, United States, 94090
      • Sean N Parker Center for Allergy & Asthma Research, LPCH El Camino Hospital
  • Illinois
    • Chicago, Illinois, United States, 60637
      • The University of Chicago Medicine
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
  • New York
    • New York, New York, United States, 10029
      • Icahn School of Medicine at Mount Sinai
  • Ohio
    • Cincinnati, Ohio, United States, 45241
      • Cincinnati Children's Hospital Medical Center
  • Washington
    • Seattle, Washington, United States, 98115
      • ASTHMA, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 15 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject has a body mass index (BMI) ≥ 3rd percentile and ≤ 97th percentile.
• Subject has a physician-diagnosed peanut allergy or history of peanut allergy. Subjects with history of nonsevere anaphylaxis (Grade ≤ 3) to peanuts (including mild wheezing or dyspnea without hypoxia) will be enrolled.
• Subject has an anti-Ara h2 Immunoglobulin E (IgE) measured by ImmunoCAP > 0.35 kU/L.
• Subject has a positive Skin prick test (SPT) to peanut with a change in wheal diameter ≥ 3 mm as compared to a negative control.
• Subject has a positive peanut Double-blinded placebo-controlled food challenge (DBPCFC) at Screen 2 visit with an eliciting dose ≤ 300 mg peanut protein (≤ 444 mg cumulative reactive dose [CRD]).

• Female subject must either:

  • Be of non-childbearing potential, clearly premenarchal; documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
  • Or, if of childbearing potential, agrees not to try to become pregnant during the study; and have a negative urine pregnancy test at screening and at day 1 (predose); and if heterosexually active, agrees to consistently use 1 form of highly effective birth control starting at screening and throughout the study period.
• Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 28 days after the final study drug administration.
• Female subject must not donate ova starting at screening and throughout the study period, and for 28 days after the final study drug administration.

• A heterosexually active male subject with female partner(s) who are of childbearing potential is eligible if:

  • Agrees to use a male condom starting at screening and continue throughout study treatment and for 28 days after the final study drug administration. If the male subject has not had a vasectomy or is not sterile, the subjects female partner(s) is utilizing 1 form of highly effective birth control starting at screening and continue throughout study treatment and for 90 days after the male subject receives his final study drug administration.
• Male subject must not donate sperm starting at screening and throughout the study period, and for 90 days after the final drug administration.
• Subject and subject's parent(s) or legal guardian agree that the subject will not participate in another interventional study while participating in the present study.

Exclusion Criteria:

• Subject has severe anaphylaxis to peanuts (Grades 4 or 5 including dyspnea associated with hypoxia, cyanosis, hypotension or neurological compromise) per the Grading of Food-Induced Anaphylaxis According to Severity of Clinical Symptoms based on historical clinical symptoms.
• Subject develops a Grade 4 or 5 reaction during the DBPCFC, per the Grading of Food- Induced Anaphylaxis According to Severity of Clinical Symptoms based on historical clinical symptoms.
• Subject has received or is planning to receive administration of any vaccine (other than injectable Influenza vaccine) from 28 days prior to the first dose through 2 weeks after the last dose of the study vaccine.
• Subject received any specific immunotherapy for allergy (e.g., epicutaneous immunotherapy [EPIT], sublingual immunotherapy [SLIT], Subcutaneous immunotherapy [SCIT] and oral immunotherapy [OIT]) during the past 12 months, currently or plans to receive during the course of the study.

• Subject has used the following drug(s) prior to the dosing of the study vaccine:

  • Within 2 months prior to study vaccine administration: Systemic (or inhaled) steroid, chemical mediator-isolation inhibitor, T helper cell type 2 (Th2) cytokine inhibitor, thromboxane A2 synthesis inhibitor, thromboxane A2 receptor antagonist, β-blocker, angiotensin-converting enzyme inhibitors and/or angiotensin-receptor blockers
  • Within 3 months prior to study vaccine administration: Biologics and/or immune modulators (including anti-TNFα antibody and anti-IgE monoclonal antibody)
• Subject has history of allergic reactions such as anaphylactic shock, angioedema with airway constriction or hypotension caused by food other than peanut and/or medical products (including vaccine) in the past.
• Subject's laboratory test results at screening or prior to study drug dosing on day 1 are outside the normal limits and are considered clinically significant.
• Subjects with anti-Lysosomal associated membrane protein (LAMP)-1 antibodies above the cut-point for the Tier 1 assay and who are confirmed positive in the Tier 2 assay at Screen 1 visit (baseline).
• Subject had a positive test result for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) antigen/antibody.
• Subject had a positive urine drug screen result.
• Subject has immune disorders (including autoimmune disease) and/or diseases requiring immunosuppressive drugs.
• Subject was diagnosed with immunodeficiency in the past.
• Subject has uncontrolled hypertension.
• Subject has a history of cardiovascular disease, arrhythmias, chronic lung disease, active eosinophilic gastrointestinal disease or any other medical or surgical conditions, which, places the subject at increased risk for participation in the study.
• Subject has a complication or medical history of respiratory disease, which requires medical treatment.
• Subject has a complication or medical history of malignant tumor.
• Subject has mental conditions such as schizophrenia, bipolar disorder, dementia or major depressive disorder.
• Subject has severe or poorly controlled atopic dermatitis or generalized eczema.
• Subject is unable to discontinue antihistamines within 7 days or 5 half-lives (whichever duration is longer) prior to SPT and oral food challenge procedures.
• Subject has asthma other than mild intermittent asthma (National Heart, Lung and Blood Institute [NHLBI] Guidelines, July 2007) and has a forced expiratory volume in 1 second value < 80% and/or requiring chronic maintenance treatment (i.e., inhaled corticosteroids).
• Subject has already received injection of Lysosomal associated membrane protein (LAMP)-vax such as ASP0892.
• Subject has received investigational therapy within 35 days or 5 half-lives, whichever is longer, prior to screening.
• Subject's parent(s) or legal guardian is an employee of the Astellas Group or vendors involved in the study.
• Subject has any condition, which, makes the subject unsuitable for study participation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ASP0892 Low Dose (Cohort A); Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.	Drug: ASP0892; Intradermal
Experimental: ASP0892 High Dose (Cohort B); After all participants in cohort A complete study procedures, the DMC will review the safety and tolerability data and provide recommendations depending on the nature, frequency and severity of the safety profile reviewed. Recommendations will be to proceed with escalation to the next higher dose or stop dose escalation (i.e., no further dosing with study drug).	Drug: ASP0892; Intradermal
Placebo Comparator: Placebo; Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.	Drug: Placebo; Intradermal; normal saline solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety as assessed by Treatment Emergent Adverse Events (TEAEs)	Adverse Events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). AEs starting or worsening after the first dose of study drug up through study completion will be considered treatment-emergent.	Up to Day 576
Safety as assessed by local reactogenicity reactions	Participants will be asked to record local reactogenicity (pain, tenderness; erythema/redness, Induration/Swelling) on a daily basis for 7 consecutive days after the injection, each treatment will be summarized. Grades range from 1 (mild) to 4 (Potentially Life Threatening).	Up to Day 50
Safety as assessed by systemic reactogenicity reactions	Participants will be asked to record systemic reactogenicity (nausea/vomiting, diarrhea, headache, fatigue, myalgia) on a daily basis for 7 consecutive days after the injection, each treatment will be summarized. Grades range from 1 (mild) to 4 (Potentially Life Threatening).	Up to Day 50
Number of participants with vital signs abnormalities and/or adverse events	Number of participants with potentially clinically significant vital sign values.	Up to Day 576
Number of participants with laboratory value abnormalities and/or adverse events	Number of participants with potentially clinically significant laboratory values.	Up to Day 576
Safety assessed by Anti-LAMP-1 antibody	Anti-LAMP-1 antibody formation for all participants will be summarized for each treatment by visit using descriptive statistics.	Up to Day 576

Collaborators and Investigators

• Sponsor: Astellas Pharma Global Development, Inc.
• Investigators: Study Director: Medical Monitor, Senior Medical Director, Astellas Pharma Global Development, Inc.

Publications and helpful links

Helpful Links

• Link to results on the Astellas Clinical Study Results website.
• Link to plain language summary of the study on the Trial Results Summaries website

Study record dates

Study Major Dates

• Study Start (Actual): March 12, 2019
• Primary Completion (Actual): October 11, 2021
• Study Completion (Actual): October 11, 2021

Study Registration Dates

• First Submitted: November 26, 2018
• First Submitted That Met QC Criteria: November 26, 2018
• First Posted (Actual): November 28, 2018

Study Record Updates

• Last Update Posted (Actual): September 21, 2022
• Last Update Submitted That Met QC Criteria: September 18, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Peanut Allergy; ASP0892
• Additional Relevant MeSH Terms: Immune System Diseases; Food Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Nut and Peanut Hypersensitivity; Peanut Hypersensitivity
• Other Study ID Numbers: 0892-CL-1002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on ww.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No